Compare Ford Motor Company (F) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Sana Biotechnology Inc — how do they compare? Ford Motor Company trades at $12.28 (market cap $48.85B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Ford Motor Company is far larger — about 58.4× Sana Biotechnology Inc's market cap, and Ford Motor Company pays a 4.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Sana Biotechnology Inc for 23 Days on average.
| F | SANA | |
|---|---|---|
Market Cap | $48.85B | $836.71M |
Volume | 57,748,965 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $5.92 |
52-Week Low | $11.21 | $2.68 |
Typical Hold Time | 104 Days | 23 Days |
Enterprise Value | $180.81B | $749.96M |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% on the day, amid a challenging quarter with a 6.6% sales decline reported for Q3 2026 (Reuters, 2026-10-02). The stock shows a bearish technical signal, with moving averages indicating a downtrend. Fundamentally, the company reported a net loss of $8.18 billion for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $21.28 billion. Recent news highlights supplier disruptions affecting F-150 production and a strategic shift toward hybrids.
The outlook for Ford is mixed, with analyst consensus leaning toward a 'Hold' (48.93% of ratings) and a price target of $15.90 suggesting potential upside. Key opportunities include the growing hybrid segment and strong commercial division, while risks involve ongoing sales volatility, high debt levels, and competitive pressures from Asian automakers. Investors should weigh the company's cash flow strength against profitability challenges and market share losses.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
